Go Back This article was viewed 89 times

Editorial


Nanobytes

Radhika A. Vaishnav
Department of Biomedical Research, Harmony Clinic and Vadodara Stroke Center, Vadodara, India
Corresponding Author:

Radhika A. Vaishnav

Department of Biomedical Research, Harmony Clinic and Vadodara Stroke Center, Vadodara, India
E-mail: radhikavaishnav@gmail.com

Corresponding Author:

Radhika A. Vaishnav

Department of Biomedical Research, Harmony Clinic and Vadodara Stroke Center, Vadodara, India
E-mail: radhikavaishnav@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20172636

ABSTRACT


The US Food and Drug Administration (FDA) recently announced its decision to go ahead with approval of existing immunotherapeutic drug Keytruda to treat cancers based on the genetic profile of a tumor rather than the type of cancer. Such a decision to approve a drug in a “site agnostic” manner is a first, with drugs traditionally approved for specific types of cancer based on location or cell type. The drug has been given the green light for individuals – adults as well as children - who have solid tumors with microsatellite instability or mismatch repair deficiency and that do not respond to other treatment. Both of these genetic changes involve impairment of the cell’s gene repair system and lead to increased mutations. Such genetic changes, although rare overall among cancers, are fairly common in colorectal, endometrial, and gastrointestinal cancers. The FDA used accelerated approval based on five clinical trials that studied it in 15 different cancer types. Almost 40% individuals saw shrinkage of tumors after receiving Keytruda. The development is encouragement for other immunotherapies in the pipeline as well - with over 200 immunotherapeutics currently in various stages of clinical trial or approval.
Keywords: Nanobytes, NGS, RT11-I, BRCA2

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.